March, 2026, In Singapore, Eutropics today announced a research collaboration with the National University of Singapore (NUS) to evaluate the company’s PRIMAB™ functional biomarker platform in Multiple Myeloma. The partnership will explore how PRIMAB’s predictive insights into tumor cell apoptosis can inform individualized therapeutic strategies for patients with this complex hematologic cancer. The study will […]

October, 2025, PRIMABS recent article in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) describes Eutropics’ PRIMAB conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict BH3‑mimetic response. Independent groups are now citing this work in the context of BH3 profiling and functional precision oncology, highlighting PRIMABS’ potential as a clinically deployable companion […]

April, 2025, Eutropics Protein/Protein interaction detectors platform is published in “Cancers” DOI: 10.3390/cancers17111852. In this We describe a new diagnostics platform based on a novel panel of antibody-based reagents that have significant research utility and potential clinical utility for the prediction of drug treatment responses or in diagnosing mechanisms underlying treatment resistance in both solid […]

December, 2024, in the United States, Eutropics and the Keck School of Medicine of the University of Southern California (USC) entered a research collaboration with the to evaluate its PRIMAB™ Dx diagnostic platform in Acute Myeloid Leukemia (AML). The study aims to assess how PRIMAB’s functional biomarker approach can help predict patient response to targeted […]

September, 2024, Eutropics Pharmaceuticals is pleased to announce an extension of its long-standing research collaboration with the University of Texas MD Anderson Cancer Center, focused on advancing the PRIMAB™ functional biomarker platform in Acute Myeloid Leukemia (AML). The renewed MTA agreement builds upon more than a decade of joint research aimed at translating insights into apoptosis […]

In June 2019, Eutropics Pharmaceuticals was awarded highly competitive funding from MassVentures’ SBIR Targeted Technologies (START) program to support the commercialization of its PraediCare Dx predictive cancer diagnostics platform. The non‑dilutive START Stage III grant builds on earlier Stage I and II awards and is aimed at accelerating PraediCare Dx’s transition from an NIH/NCI‑funded SBIR […]

September, 2018, Eutropics Pharmaceuticals has been selected for a prestigious NIH/NCI SBIR Phase IIB Bridge Award providing 3 million dollars in non‑dilutive matching funds tied to commercial revenues generated from its PraediCare functional precision oncology platform. This award is designed to bridge the critical gap between completion of Phase II SBIR work and large‑scale market […]